Latest Period
Q1 2026
Security Snapshot
Mineralys Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MLYS) Institutional Ownership
CUSIP: 603170101
13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026
Institutions Reporting
212
Shares (Excl. Options)
90,325,190
Price
$27.09
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- MLYS on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 90,325,190
- Total 13F value
- $2,455,036,190
- Portfolio coverage rank
- 0.01%
- Share change
- +2,096,024
- Value change
- -$6,333,187
- Number of holders
- 212
- Shares outstanding
- 79,235,030
- SEC-reported price per share
- $28.49
- Insider filing price
- $28.49
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- MLYS - Mineralys Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 603170101.
- 212 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 223 to 212 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $3,207,524,350 to $2,455,036,190.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 212 institutions filings for Q1 2026.
Security key
603170101
Latest holder period
Q1 2026
13F holders
212
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
MLYS full holder history
Mineralys Therapeutics, Inc. SEC filings
Mineralys Therapeutics, Inc. company facts
Mineralys Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 603170101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
7
Security
MLYS
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Catalys Pacific Fund, LP | 10% | -24% | $267,051,367 | -$32,576,328 | 8,002,738 | -11% | Catalys Pacific Fund, LP | 31 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $104,939,988 | +$20,308,933 | 7,796,433 | +24% | RA Capital Management, L.P. | 04 Sep 2025 |
| Samsara BioCapital, L.P. | 8.2% | -10% | $85,419,771 | +$8,209,106 | 6,346,194 | +11% | Srinivas Akkaraju | 04 Sep 2025 |
| FMR LLC | 6.3% | $182,087,409 | 5,017,509 | FMR LLC | 31 Dec 2025 | |||
| BlackRock, Inc. | 5.2% | $149,286,258 | 4,113,657 | BlackRock, Inc. | 31 Dec 2025 | |||
| Andera Partners | 4.2% | $39,747,075 | 2,765,976 | Andera Partners | 30 Jun 2025 | |||
| ADAMS STREET PARTNERS LLC | 2.3% | $15,320,183 | 1,129,807 | Adams Street Partners, LLC | 31 Dec 2024 |
As of 31 Mar 2026, 212 institutional investors reported holding 90,325,190 shares of Mineralys Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MLYS). This represents 114% of the company’s total 79,235,030 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
83%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Catalys Pacific, LLC | 10% | 7,903,838 | 0% | 93% | $214,114,971 |
| RA CAPITAL MANAGEMENT, L.P. | 9.7% | 7,692,750 | +5% | 2.2% | $208,396,598 |
| SAMSARA BIOCAPITAL, LLC | 7.4% | 5,871,018 | 0% | 15% | $159,045,878 |
| FMR LLC | 6.1% | 4,861,104 | -3.9% | 0.01% | $131,687,318 |
| BlackRock, Inc. | 5.7% | 4,481,582 | +3.6% | 0% | $121,406,057 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.2% | 3,359,068 | +328% | 0.02% | $90,997,151 |
| STATE STREET CORP | 3.7% | 2,935,940 | -7.8% | 0% | $79,534,615 |
| Caligan Partners LP | 3.5% | 2,772,654 | 0% | 5.3% | $75,111,197 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 2,454,363 | 0% | 0% | $66,488,694 |
| Laurion Capital Management LP | 2.8% | 2,232,040 | +30% | 5.7% | $60,465,964 |
| ORBIMED ADVISORS LLC | 2.6% | 2,052,900 | +109% | 1.3% | $55,613,061 |
| Point72 Asset Management, L.P. | 2.4% | 1,911,433 | +58% | 0.09% | $51,780,720 |
| FRANKLIN RESOURCES INC | 2.3% | 1,784,662 | -0.23% | 0.01% | $48,346,494 |
| ANDERA PARTNERS | 2% | 1,591,917 | 0% | 24% | $43,125,032 |
| SR One Capital Management, LP | 2% | 1,563,966 | 0% | 4.6% | $42,367,839 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1.9% | 1,538,662 | 0% | 1.1% | $41,682,354 |
| Polar Capital Holdings Plc | 1.9% | 1,500,749 | +7.1% | 0.18% | $40,655,290 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.7% | 1,343,313 | +1.4% | 0% | $36,391,000 |
| SPHERA FUNDS MANAGEMENT LTD. | 1.7% | 1,339,971 | +198% | 6.2% | $36,299,814 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 1,301,135 | +3.5% | 0% | $35,254,696 |
| JENNISON ASSOCIATES LLC | 1.6% | 1,266,174 | +0.6% | 0.02% | $34,300,654 |
| ARMISTICE CAPITAL, LLC | 1.5% | 1,176,000 | +74% | 1.1% | $31,857,840 |
| BANK OF AMERICA CORP /DE/ | 1.4% | 1,100,372 | +11% | 0% | $29,809,078 |
| Pictet Asset Management Holding SA | 1.3% | 1,034,438 | +21% | 0.03% | $28,022,925 |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.3% | 1,001,728 | +0.97% | 0.64% | $27,136,812 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Latest
Q1 2026
Rows shown
1-13 of 13
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 90,325,190 | $2,455,036,190 | -$6,333,187 | $27.09 | 212 |
| 2025 Q4 | 88,390,661 | $3,207,524,350 | +$270,032,812 | $36.29 | 223 |
| 2025 Q3 | 79,306,949 | $3,007,317,130 | +$505,416,563 | $37.92 | 191 |
| 2025 Q2 | 65,687,280 | $888,767,559 | +$52,640,107 | $13.53 | 164 |
| 2025 Q1 | 61,178,854 | $971,385,613 | +$245,430,113 | $15.88 | 148 |
| 2024 Q4 | 46,486,259 | $572,248,542 | +$24,847,746 | $12.31 | 108 |
| 2024 Q3 | 44,382,325 | $540,052,185 | +$2,379,010 | $12.11 | 105 |
| 2024 Q2 | 44,151,028 | $516,569,023 | +$24,151,320 | $11.70 | 93 |
| 2024 Q1 | 41,871,642 | $540,562,541 | +$93,970,804 | $12.91 | 91 |
| 2023 Q4 | 34,713,391 | $298,534,855 | -$5,432,193 | $8.60 | 87 |
| 2023 Q3 | 26,512,068 | $252,135,025 | -$9,247,223 | $9.51 | 77 |
| 2023 Q2 | 25,186,898 | $429,224,695 | +$10,759,767 | $17.05 | 68 |
| 2023 Q1 | 24,614,198 | $385,431,208 | +$385,431,208 | $15.66 | 66 |